Progenics Pharma Balance Sheet - Annual (NASDAQ:PGNX)

Add to My Stocks
$8.44 $0.14 (1.69%) PGNX stock closing price Mar 16, 2018 (Closing)

The financial analysis of a company like Progenics Pharma involves checking the three financial statements of the company in detail, of which the balance sheet is one. Financial strength can be guaged by performing Progenics Pharma stock analysis and by analyzing the balance sheet. Good annual results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Progenics Pharma had a long term debt of $49.45M at the end of 2016. To understand the debt servicing capacity of the company, one needs to look at Progenics Pharma operating cash flow and Progenics Pharma revenue also. Progenics Pharma debt to equity ratio is 0.78.

View latest 10 year balance sheet data to check Progenics Pharma financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec201620152014201320122011201020092008
Marketable Securities-------1.5M63.12M
Raw Materials---------
Work In Progress---------
Finished Goods---------
Notes Receivable---------
Other Current Assets4.32M5.63M2.51M1.94M1.69M-1.8M1.46M3.53M
Total Current Assets
Property Plant & Equipment5.59M12.67M12.37M14.53M15.66M26.09M30.05M27.91M27.69M
Accumulated Depreciation-10.27M9.82M12.11M12.27M22.06M24.17M21.35M16.62M
Net Property Plant & Equipment
Investment & Advances---2.2M3.24M3.33M3.6M3.79M22.06M
Other Non-Current Assets---------
Deferred Charges----2.05M----
Deposits & Other Assets2.47M1.69M----1.25M1.86M-
Total Assets
Notes Payable---------
Accounts Payable-9.54M6.57M6.51M5.64M6.33M9.68M5.83M6.49M
Current Portion Long-Term Debt---------
Current Portion Capital Leases---------
Accrued Expenses15.76M--------
Income Taxes Payable----2.06M----
Other Current Liabilities--------31.7M
Total Current Liabilities
Deferred Taxes/Income13.01M11.19M11.33M12.32M-----
Convertible Debt---------
Long-Term Debt49.45M--------
Non-Current Capital Leases---------
Other Long-Term Liabilities15.4M19.66M18.11M16.61M1.07M1.49M1.63M--
Total Liabilities
Minority Interest---------
Preferred Stock---------
Common Stock Net---------
Capital Surplus598.06M594.51M589.82M548.51M493.61M463.44M453.35M439.94M422.08M
Retained Earnings-490.57M-501.37M-462.26M-466.67M-424.1M-388.67M-399.05M-329.33M-298.71M
Treasury Stock2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M
Other Liabilities-0.08M---0.19M-0.26M-0.26M-0.29M-0.3M-1.29M
Shareholders Equity104.76M90.66M124.9M78.97M66.56M71.8M51.3M107.6M119.36M
Total Liabilities & Shareholders Equity198.98M131.25M161.03M114.54M76.3M80.11M62.73M113.61M157.83M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The latest Progenics Pharma stock price, and Progenics Pharma historical stock prices show the stock price movement over time, and the Progenics Pharma PE ratio chart displays the PE ratio movement. Apart from stock price, one should also look at balance sheet items which mainly comprise of the following:

  • Assets: An asset is a resource that a corporation like Progenics Pharma owns and has monetary significance. PGNX assets grew from $131.25M in 2015 to $198.98M in 2016. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. PGNX stock had total liabilities of $94.22M for the year 2016.

Progenics Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio